CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts have a consensus rating of "Moderate Buy" on CAMP4 (5 buys, 1 hold, 1 sell) with an average 12‑month price target of $8.60; recent notes include Rodman initiating a buy at $7 and Leerink raising its target to $9.
• The company missed quarterly EPS estimates, reporting -$0.87 vs. consensus -$0.31 on $0.35M revenue, and shows deeply negative ROE and net margin; sell‑side forecasts about -$0.78 EPS for the current fiscal year.
• Shares trade near $4.05 (50‑day/200‑day SMAs ~$4.66/$4.59) with a market cap of ~$210M, and institutional investors like Janus Henderson, Balyasny and Adage have significantly increased or built positions.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $8.60.

A number of brokerages have commented on CAMP. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a "buy" rating and a $7.00 price target on the stock. Leerink Partners lifted their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Thursday, April 2nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th.

CAMP4 Therapeutics Price Performance

Shares of CAMP4 Therapeutics stock opened at $4.05 on Friday. The business's 50 day simple moving average is $4.66 and its two-hundred day simple moving average is $4.59. The stock has a market capitalization of $210.30 million, a P/E ratio of -1.52 and a beta of 0.04. CAMP4 Therapeutics has a one year low of $1.30 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.56). The company had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 162.49% and a negative net margin of 2,298.54%. Sell-side analysts expect that CAMP4 Therapeutics will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of large investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in shares of CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock worth $38,807,000 after buying an additional 1,666,666 shares during the last quarter. EcoR1 Capital LLC bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $1,992,000. Balyasny Asset Management L.P. bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $14,938,000. 683 Capital Management LLC bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $775,000. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of CAMP4 Therapeutics by 11.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider's stock worth $13,374,000 after buying an additional 220,895 shares during the last quarter.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.